<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130910</url>
  </required_header>
  <id_info>
    <org_study_id>06-1127-D03</org_study_id>
    <secondary_id>NIH 5 P30 AI027757-19</secondary_id>
    <secondary_id>UW Royalty Research Fund #3335</secondary_id>
    <nct_id>NCT00130910</nct_id>
  </id_info>
  <brief_title>Treatment of Helminth co-Infection: Short-Term Effects on HIV-1 Progression Markers and Immune Activation</brief_title>
  <official_title>Randomized, Double Blind, Placebo Controlled Trial of Albendazole in Soil-Transmitted Helminth and HIV-1 co-Infected Kenyan Individuals to Determine the Effect of Such Treatment on HIV-1 Disease Progression and Genital Shedding.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kenya Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenyatta National Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identifying methods to slow disease progression in patients with HIV-1 infection remains a
      top priority in many regions of the world. In many countries, medications known to slow
      progression are not readily affordable or available. Many of the individuals living in these
      countries are also co-infected with a variety of other diseases such as tuberculosis, malaria
      and soil-transmitted helminths. There are data to suggest that infection with these agents
      may activate the immune system in HIV-1 co-infected individuals and may lead to more rapid
      HIV disease progression. This study will evaluate the potential impact of treating helminths
      in HIV-1 seropositive individuals. Markers of disease progression and immune activation will
      be assessed. We will also measure the amount of virus in genital secretions to determine if
      treatment of co-infection can reduce the infectiousness of HIV in these individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many HIV infected individuals live in crowded urban settings. These conditions are associated
      with repeated intestinal parasite infections (helminths), which may alter the immune system
      in individuals with HIV and AIDS. This alteration in the immune system may increase both the
      susceptibility to other infections and the severity of these infections in these individuals.
      Prior studies have shown that in HIV infected individuals, intestinal parasites are
      associated with increased levels of the HIV virus circulating in the blood. Studies have also
      clearly shown that in individuals with HIV, progression to AIDS can be predicted by the
      quantity of HIV virus detectable within the blood. It is important to determine whether
      treating helminth co-infection in patients with HIV will help individuals control HIV
      infection and slow disease progression.

      The investigators propose a study to characterize the short-term effect of antihelminth
      therapy on HIV disease progression, markers of immune activation and levels of HIV in genital
      secretions. They also plan to determine the prevalence of helminth infection in individuals
      with HIV. This study will examine factors that might affect an individual's risk of helminth
      infection, such as CD4 count, viral load, age, gender and duration of time spent in an urban
      setting. In addition, the investigators will conduct a randomized clinical trial to determine
      the effect of treating helminth infection on markers of immune activation, HIV disease
      progression and risk of transmission as measured by HIV-1 RNA in genital secretions. The
      study will be conducted in a group of HIV infected individuals in and around Nairobi, Kenya
      who do not yet meet criteria for highly active antiretroviral therapy (HAART).

      Identifying inexpensive and practical methods to delay HIV progression offers tremendous
      public health benefits. At the present time, highly active antiretroviral therapy is being
      rapidly scaled up in resource poor settings. The demand for these drugs currently far
      outweighs the capacity for such services to be provided in many regions. For the millions of
      people infected by HIV in resource poor settings, delaying immunosuppression for months to
      years could allow important developments in infrastructure which would permit the maximum
      number of individuals to benefit from highly active antiretroviral therapy.

      HIV-1 infected adults will be invited to participate in the trial. Women whose pregnancy test
      is positive will be excluded from the study. A physical examination will be conducted on all
      prospective clients, and those found to have clinical pallor, or signs and symptoms of active
      tuberculosis, malaria or malignancy will be excluded from the study. Individuals with CD4
      counts greater than 250 cells/mm3 will be enrolled in the study following written informed
      consent.

      HIV-1 infected patients who meet inclusion and exclusion criteria will be enrolled for
      screening. Stool samples will be collected at enrollment and evaluated for ova and parasites.
      All patients who are found to have positive stool parasite examinations and who consent to
      participate will be enrolled in the treatment phase of the study. Those who are found to have
      negative stool specimens will not continue to the treatment phase. Baseline demographic and
      socio-economic data will be collected from these patients in order to evaluate the prevalence
      and correlates of helminth infection among HIV-1 infected individuals. Those who are found to
      be infected with helminths but who decline to participate in the treatment phase will be
      treated at no charge with a three day course of albendazole (400 mg/day) by the study
      investigators. Those patients who are enrolled in the treatment phase will have blood
      collected for baseline plasma HIV-1 RNA levels. Computer-generated random number allocation
      will be used to assign treatment group. The pharmacy at the Kenya Medical Research Institute
      will be responsible for the determination of randomization group and distribution of
      albendazole and placebo. The pharmacy will also be responsible for maintaining records
      regarding treatment group. Treatment will be provided in the form of a six 200 mg pills of
      albendazole or six placebo pills identical in appearance. Both placebo and albendazole will
      be provided in an identical appearing envelope. Treatment arms consist of either initial
      therapy with albendazole (400 mg per day for three days) or two placebo pills per day
      initially. All patients will be required to visit the clinic twelve weeks after enrollment.
      At this twelve week visit, stool samples will again be collected for evaluation of helminth
      infection. Plasma CD4 count and HIV-1 RNA level measurements will be repeated at this twelve
      week visit. All patients who received placebo initially as well as all patients with evidence
      of helminth infection will be treated with open-label albendazole therapy regardless of
      initial treatment arm. At enrollment and the twelve week visit, lymphocytes will also be
      isolated from serum samples for assessment of immune activation markers. Genital HIV-1 RNA
      levels will be compared in 100 individuals randomized to immediate versus deferred
      antihelminthics at baseline and at the 3-month visit (prior to receiving deferred therapy).
      This will provide data quantifying the potential effect of anti-helminthic treatment on
      genital HIV-1 RNA. Consenting adults will have genital swabs collected (semen or
      cervical/vaginal) and placed in freezing media prior to cryopreservation and transport to
      Fred Hutchinson Cancer Research Center for HIV-1 RNA assays.

      Patients who do not follow-up as directed will be contacted by the administrative support
      team at their homes in order to determine the reason for each loss to follow up. Any adverse
      events during the treatment period will be reported and managed accordingly at the treatment
      clinic.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in markers of HIV-1 disease progression</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CD4 count</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HIV-1 RNA level</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Genital HIV-1 RNA levels</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune activation markers of global T cell activation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of CD4+ and CD8+ T cells expressing Ki67</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Na√Øve and memory T cell subsets</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type and number of helminth co-infections</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">234</enrollment>
  <condition>HIV Infections</condition>
  <condition>Helminthiasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Albendazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>Albendazole 400mg x 3 first dose observed</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zentel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Albendazole Placebo 400mg x 3 first dose observed</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must not be or have been on highly active antiretroviral therapy.

          -  Participants must have a CD4 count greater than 250 cells/mm3.

          -  Participants must be at least 18 years of age.

          -  Participants must be able and willing to participate and give written informed
             consent.

          -  Participants must be able and willing to return for the scheduled follow-up visits.

          -  In addition, in order to be included in the treatment phase of the study, patients
             must have at least one stool specimen positive for a soil transmitted helminth.

        Exclusion Criteria:

          -  Participants who have received treatment for helminth infection in the past 6 months
             (by self report or chart review).

          -  Participants must not be pregnant at the time of treatment (by urine HCG testing).

          -  Participants who present with other serious co-morbidities such as severe anaemia,
             malaria or tuberculosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judd L Walson, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grace C. John-Stewart, MD, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenya Medical Research Institute</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <reference>
    <citation>2004 report on the global AIDS epidemic : 4th global report. UNAIDS</citation>
  </reference>
  <reference>
    <citation>Fincham JE, Markus MB, Adams VJ. Could control of soil-transmitted helminthic infection influence the HIV/AIDS pandemic. Acta Trop. 2003 May;86(2-3):315-33.</citation>
    <PMID>12745148</PMID>
  </reference>
  <reference>
    <citation>Elliott AM, Mawa PA, Joseph S, Namujju PB, Kizza M, Nakiyingi JS, Watera C, Dunne DW, Whitworth JA. Associations between helminth infection and CD4+ T cell count, viral load and cytokine responses in HIV-1-infected Ugandan adults. Trans R Soc Trop Med Hyg. 2003 Jan-Feb;97(1):103-8.</citation>
    <PMID>12886815</PMID>
  </reference>
  <reference>
    <citation>Bentwich Z, Weisman Z, Moroz C, Bar-Yehuda S, Kalinkovich A. Immune dysregulation in Ethiopian immigrants in Israel: relevance to helminth infections? Clin Exp Immunol. 1996 Feb;103(2):239-43.</citation>
    <PMID>8565306</PMID>
  </reference>
  <reference>
    <citation>Kassu A, Tsegaye A, Wolday D, Petros B, Aklilu M, Sanders EJ, Fontanet AL, Van Baarle D, Hamann D, De Wit TF. Role of incidental and/or cured intestinal parasitic infections on profile of CD4+ and CD8+ T cell subsets and activation status in HIV-1 infected and uninfected adult Ethiopians. Clin Exp Immunol. 2003 Apr;132(1):113-9.</citation>
    <PMID>12653845</PMID>
  </reference>
  <reference>
    <citation>Elliott AM, Kyosiimire J, Quigley MA, Nakiyingi J, Watera C, Brown M, Joseph S, French N, Gilks CF, Whitworth JA. Eosinophilia and progression to active tuberculosis in HIV-1-infected Ugandans. Trans R Soc Trop Med Hyg. 2003 Jul-Aug;97(4):477-80.</citation>
    <PMID>15259486</PMID>
  </reference>
  <reference>
    <citation>Olsen A. The proportion of helminth infections in a community in western Kenya which would be treated by mass chemotherapy of schoolchildren. Trans R Soc Trop Med Hyg. 1998 Mar-Apr;92(2):144-8.</citation>
    <PMID>9764316</PMID>
  </reference>
  <reference>
    <citation>Wolday D, Mayaan S, Mariam ZG, Berhe N, Seboxa T, Britton S, Galai N, Landay A, Bentwich Z. Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):56-62.</citation>
    <PMID>12352151</PMID>
  </reference>
  <reference>
    <citation>Lawn SD, Karanja DM, Mwinzia P, Andove J, Colley DG, Folks TM, Secor WE. The effect of treatment of schistosomiasis on blood plasma HIV-1 RNA concentration in coinfected individuals. AIDS. 2000 Nov 10;14(16):2437-43.</citation>
    <PMID>11101053</PMID>
  </reference>
  <reference>
    <citation>Bennett A, Guyatt H. Reducing intestinal nematode infection: efficacy of albendazole and mebendazole. Parasitol Today. 2000 Feb;16(2):71-4. Review.</citation>
    <PMID>10652492</PMID>
  </reference>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2005</study_first_submitted>
  <study_first_submitted_qc>August 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2005</study_first_posted>
  <last_update_submitted>November 13, 2007</last_update_submitted>
  <last_update_submitted_qc>November 13, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 15, 2007</last_update_posted>
  <keyword>HIV</keyword>
  <keyword>Helminthiasis</keyword>
  <keyword>Co-infection</keyword>
  <keyword>Intestinal immune activation</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Coinfection</mesh_term>
    <mesh_term>Helminthiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

